Clinical efficacy and safety of cefepime–tazobactam in hospitalized patients in South India

Bansal, N.K.; Sukhwani, Kalpesh; D, Suresh Kumar; Nambi, P Senthur; Gopalakrishnan, Ram; Ramasubramanian, V

doi:10.1080/23744235.2017.1410284

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical experience is reported only from India. In a retrospective study from India, 154 patients were treated with cefepime-tazobactam, mainly for pneumonia (31%) or UTI (23%) caused by ESBL-producing Klebsiella pneumoniae or E. coli (234). Twenty-nine percent of patients were admitted to an ICU.…”

Section: Blblis In Development Processmentioning

confidence: 99%

New β-Lactam–β-Lactamase Inhibitor Combinations

et al. 2020

View full text Add to dashboard Cite

SUMMARY The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of in vitro activities, mechanisms of resistance, and pharmacokinetic-pharmacodynamic (PK-PD) characteristics. A summary of available clinical data is provided per drug. Four approved BLBLIs are discussed in detail. All are options for treating multidrug-resistant (MDR) Enterobacterales and Pseudomonas aeruginosa. Ceftazidime-avibactam is a potential drug for treating Enterobacterales producing extended-spectrum β-lactamase (ESBL), Klebsiella pneumoniae carbapenemase (KPC), AmpC, and some class D β-lactamases (OXA-48) in addition to carbapenem-resistant Pseudomonas aeruginosa. Ceftolozane-tazobactam is a treatment option mainly for carbapenem-resistant P. aeruginosa (non-carbapenemase producing), with some activity against ESBL-producing Enterobacterales. Meropenem-vaborbactam has emerged as treatment option for Enterobacterales producing ESBL, KPC, or AmpC, with similar activity as meropenem against P. aeruginosa. Imipenem-relebactam has documented activity against Enterobacterales producing ESBL, KPC, and AmpC, with the combination having some additional activity against P. aeruginosa relative to imipenem. None of these drugs present in vitro activity against Enterobacterales or P. aeruginosa producing metallo-β-lactamase (MBL) or against carbapenemase-producing Acinetobacter baumannii. Clinical data regarding the use of these drugs to treat MDR bacteria are limited and rely mostly on nonrandomized studies. An overview on eight BLBLIs in development is also provided. These drugs provide various levels of in vitro coverage of carbapenem-resistant Enterobacterales, with several drugs presenting in vitro activity against MBLs (cefepime-zidebactam, aztreonam-avibactam, meropenem-nacubactam, and cefepime-taniborbactam). Among these drugs, some also present in vitro activity against carbapenem-resistant P. aeruginosa (cefepime-zidebactam and cefepime-taniborbactam) and A. baumannii (cefepime-zidebactam and sulbactam-durlobactam).

show abstract

Section: Blblis In Development Processmentioning

confidence: 99%

New β-Lactam–β-Lactamase Inhibitor Combinations

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The spectrum of activity of cefepime/tazobactam includes Enterobacterales that are AmpC-, ESBL-, K1-, or OXA-48-β-lactamase-producing, while KPC- and NDM-producing Enterobacterales are mostly resistant [ 32 ]. An interventional RCT comparing cefepime–tazobactam versus meropenem for cUTI is ongoing, while clinical experience is reported only from India in a retrospective study in which clinical improvement was documented in 142 patients (92.2%) among 154 patients [ 120 , 121 ].…”

Section: Available Treatments For Carbapenem-resistant Gram-negative ...mentioning

confidence: 99%

Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion

et al. 2022

View full text Add to dashboard Cite

Antimicrobial resistance represents a serious threat for global health, causing an unacceptable burden in terms of morbidity, mortality and healthcare costs. In particular, in 2017, carbapenem-resistant organisms were listed by the WHO among the group of pathogens for which novel treatment strategies are urgently needed. Fortunately, several drugs and combinations have been introduced in recent years to treat multi-drug-resistant (MDR) bacteria. However, a correct use of these molecules is needed to preserve their efficacy. In the present paper, we will provide an overview on the epidemiology and mechanisms of resistance of the most common MDR Gram-negative bacteria, proposing a treatment algorithm for the management of infections due to carbapenem-resistant bacteria based on the most recent clinical evidence.

show abstract

Clinical efficacy and safety of cefepime–tazobactam in hospitalized patients in South India

Cited by 2 publications

References 7 publications

New β-Lactam–β-Lactamase Inhibitor Combinations

New β-Lactam–β-Lactamase Inhibitor Combinations

Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion

Contact Info

Product

Resources

About